GlassScriptPhysician profile
Apurva Patel
NPI 1821355074
$87,024.97
in general payments reported to CMS, 2019-2025
31 companies · $3,602 in 2025
The $3,602 reported for 2025 was more than what 78% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,594 · 2020: $1,520 · 2021: $2,639 · 2022: $3,898 · 2023: $56K · 2024: $17K · 2025: $3,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Food and Beverage: $6,992 · Travel and Lodging: $4,588 · Consulting Fee: $1,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,325.00 |
| Food and Beverage | $6,992.36 |
| Travel and Lodging | $4,588.20 |
| Consulting Fee | $1,467.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $70,249.74 | 2021-2025 | Corevalve Evolut R, Acist Rxi System, Onyx Frontier |
| Abbott Laboratories | $4,907.18 | 2019-2025 | Triclip, Diamondback Coronary, Ultreon |
| Boston Scientific Corporation | $3,706.90 | 2019-2025 | Avvigo Guidance System, General - Therapies, Emblem Mri S-Icd |
| Edwards Lifesciences Corporation | $1,494.02 | 2020-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Philips North America LLC | $1,149.35 | 2020-2024 | (Bq9) Coronary Ivus |
| Cardiovascular Systems INC. | $1,053.78 | 2019-2022 | |
| Shockwave Medical, INC | $1,036.83 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Bard Peripheral Vascular, INC. | $572.42 | 2019-2022 | |
| Amgen INC. | $459.14 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $301.83 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $280.28 | 2019-2022 | |
| Cleerly, INC. | $259.48 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Heartflow, INC. | $232.31 | 2023 | Ffrct |
| Actelion Pharmaceuticals US, INC. | $228.22 | 2019-2021 | |
| Astellas Pharma US INC | $178.99 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bolton Medical INC | $141.76 | 2021 | |
| Medtronic Vascular, INC. | $119.77 | 2019 | |
| Esperion Therapeutics, INC. | $107.50 | 2021-2022 | |
| Livanova USA, INC. | $93.18 | 2019 | |
| Saranas, INC. | $72.49 | 2022 | |
| Janssen Pharmaceuticals, INC | $51.66 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $44.15 | 2024 | Verquvo |
| Chiesi USA, INC. | $41.43 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $40.58 | 2024 | |
| Spectrawave, INC | $39.55 | 2024-2025 | Hypervue Imaging System, Starlight Imaging Catheter |
| Impulse Dynamics (USA) INC. | $35.47 | 2022 | |
| Ancora Heart, INC. | $35.34 | 2025 | Accucinch |
| Arbor Pharmaceuticals, INC. | $34.66 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.14 | 2021 | |
| Mallinckrodt Hospital Products INC. | $18.94 | 2020 | |
| Penumbra, INC. | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Apurva Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.